Atypical Genetic Basis of Pyrazinamide Resistance in Monoresistant Mycobacterium tuberculosis
Samuel J. Modlin, Tyler Marbach, Jim Werngren, Mikael Mansjö, Sven Hoffner, Faramarz Valafar
Abstract
Pyrazinamide (PZA) is a widely used antitubercular chemotherapeutic. Typically, PZA resistance (PZA-R) emerges in Mycobacterium tuberculosis strains with existing resistance to isoniazid and rifampin (i.e., multidrug resistance [MDR]) and is conferred by loss-of-function pncA mutations that inhibit conversion to its active form, pyrazinoic acid (POA).
Topics & Concepts
PyrazinamideMycobacterium tuberculosisIsoniazidMicrobiologyTuberculosisMultiple drug resistanceBiologyDrug resistanceVirologyMedicinePathologyTuberculosis Research and EpidemiologyMycobacterium research and diagnosisCancer therapeutics and mechanisms